Marbls_logo_1c
Marbls_logo_1c
CLIENT CASE STUDIES

Top Pharma Manufacturer, IPAY 2026 MFP Implementation​

A Large Pharma manufacturer engaged Marbls to ensure an on‑time IPAY 2026 Maximum Fair Price (MFP) implementation by January 1, 2026. The engagement involved leading, orchestrating, and coordinating activities across BRG, Model N, and multiple integrated system teams. The scope also included supporting the IRA Director in defining and designing the end‑to‑end MFP processes, including the complex interactions with the 340B Rebate Model.​

CHALLENGES

  • Highly compressed timeline with project launching in mid-2025 and incomplete requirements with limited impact analysis across Gross To Net, Government Pricing, Model N, and related integrations​
  • IPAY 2026 business strategy pending definition
  • Multiple parallel projects with high interdependencies requiring tight coordination and proactive risk mitigation (SAP upgrade, Model N Cloud migration, 340B Rebate Model implementation)​
  • Evolving CMS and MTF guidelines, templates and processes through mid-December 2025 and highly constrained test cycles across CMS, BRG, and the company’s internal platforms​

SOLUTION

  • Established a dedicated IRA/MFP PMO with clear governance, defined decision‑making authority, and structured escalation paths, supported by integrated collaboration across key subject‑matter experts​​
  • Aligned cross‑functional teams on the operational and system changes required for implementation by developing the MFP end‑to‑end process flow as the foundational baseline​
  • Structured a methodical approach for design, implementation, integration, and thorough test‑execution cycles, including:​
    • Model N system functionality​
    • BRG Beacon platform integrations​
    • Communication plans and Change Management aspects​
    • Framework for CMS guidance updates and compliance requirements

RESULTS

  • Seamless MFP cutover, deployment, and successful January 1, 2026 Go-live​
  • Timely and accurate rebate payment processes aligned with MFP requirements​
  • Purpose-built chargeback process design to support MFP logic and compliance​
  • End-to-end system integration across BRG Beacon, Model N, and all downstream platforms​
  • Integrated downstream reporting via platforms such as Power BI and CDL​
  • Strategic roadmap for 2026 system and process enhancements in preparation for IPAY 2027​​

You may also be interested in these related case studies

A Large Pharma manufacturer engaged Marbls to ensure an on‑time IPAY 2026 Maximum Fair Price (MFP) implementation by January 1, 2026. The engagementinvolved leading, orchestrating, and coordinating activities across BRG, Model N, and multiple integrated system teams. The scope also included supporting the IRADirector in defining and designing the end‑to‑end MFP processes, including the complex interactions with the 340B Rebate Model.​

Marbls partners with pharmaceutical and medical device and diagnostic manufacturers to provide practical, innovative services that address complex pricing, contracting and commercial excellence needs — driving the path of critical drugs, devices, and diagnostics to market. We invest in the long-term success of our clients by investing in our employees. As a team with world-class experience and a client-first philosophy, we create long-term relationships based on success, service and trust. Our approach is results-driven, hands-on and flexible to address the unique internal and external dynamics impacting our clients.

Linkedin

Headquarters
182 Nassau Street, Suite 204
Princeton, NJ 08542, United States
+1 609 285 2187

European Headquarters
Rue du Prince 9-11
1204 Geneva, Switzerland
+41 22 700 07 07

Poland Office
Ostródzka 38Z
03-289 Warszawa, Poland

Portugal Office
Rua Santa Joana Princesa, Odivelas, Lisboa, Portugal

themarblsteam@marblsgroup.com

Linkedin

© Copyright 2026 | Privacy Policy | Back to Top